Welcome to our dedicated page for Edgewise Therapeutics news (Ticker: EWTX), a resource for investors and traders seeking the latest updates and insights on Edgewise Therapeutics stock.
Edgewise Therapeutics, Inc. reports developments from its muscle disease biopharmaceutical pipeline, including sevasemten for Becker and Duchenne muscular dystrophies and cardiac sarcomere modulators such as EDG-7500 and EDG-15400 for serious cardiac conditions. Company updates commonly cover clinical data presentations, open-label extension findings, trial-program progress, and financial results tied to research and development activity.
Recurring EWTX news also includes scientific-conference participation, Nasdaq inducement equity grants under the 2024 Inducement Equity Incentive Plan, and corporate communications about its focus on muscle physiology, dystrophinopathies, hypertrophic cardiomyopathy, and heart failure.
Edgewise Therapeutics (NASDAQ: EWTX) has appointed Jonathan C. Fox, M.D., Ph.D., FACC, to its Board of Directors. Dr. Fox, currently President and CMO at BridgeBio Pharma and former CMO at MyoKardia, brings extensive experience in cardiovascular clinical development. His expertise will support Edgewise's advancement of EDG-7500, a novel therapy for hypertrophic cardiomyopathy, with a Phase 1 trial expected in late 2023. Dr. Fox's background includes pivotal roles in the development of Camzyos® (mavacamten), emphasizing his capability to boost Edgewise's leadership in cardiovascular therapies.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company, will present at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 9:10 am ET. The presentation will be webcast live, with a replay available afterward. Edgewise focuses on developing small molecule therapies for muscle disorders, including its lead candidate, EDG-5506, which targets dystrophinopathies. The company is also advancing EDG-7500 for hypertrophic cardiomyopathy. Further details can be found on their website.
Edgewise Therapeutics (NASDAQ: EWTX) announced the presentation of EDG-7500, a first-in-class oral therapy for hypertrophic cardiomyopathy (HCM), at the American College of Cardiology's 72nd Annual Scientific Session on March 5, 2023. This investigational drug aims to normalize excess cardiac contraction and improve impaired relaxation, addressing both obstructive and non-obstructive HCM. Key findings include significant improvements in cardiovascular pathophysiologies and potent gradient reductions. The company plans to initiate a Phase 1 trial for EDG-7500 in late 2023, supporting further clinical development based on promising preclinical data.
Edgewise Therapeutics (NASDAQ: EWTX) announced significant advancements in clinical trials for EDG-5506 targeting muscular dystrophies. Phase 2 trials for Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD) have shown promising developments, with interim data expected in late 2023. The company also initiated IND-enabling studies for EDG-7500, a new treatment for hypertrophic cardiomyopathy, set to begin Phase 1 trials in the second half of 2023. As of December 31, 2022, Edgewise reported cash and marketable securities totaling $352 million and a net loss of $19.4 million for Q4.
Edgewise Therapeutics (EWTX), a clinical-stage biopharmaceutical company, announced its participation in the virtual SVB Securities Global Biopharma Conference on February 14, 2023, at 1:00 pm ET. The presentation will be streamed live with a replay available afterward. Edgewise focuses on developing innovative treatments for severe neuromuscular and cardiac disorders, with its lead candidate, EDG-5506, in clinical trials for various muscular dystrophies. Additionally, the company is progressing EDG-7500, a novel treatment for hypertrophic cardiomyopathy. For more details, visit Edgewise's website.
Edgewise Therapeutics (NASDAQ: EWTX) announced its participation in the J.P. Morgan 41st Annual Healthcare Conference on January 10, 2023, at 9:45 am PT (12:45 pm ET). The presentation will be available via a live webcast, with a replay option post-event. Edgewise focuses on developing targeted therapies for severe muscle disorders, including its lead candidate, EDG-5506, aimed at treating Duchenne muscular dystrophy. The company is advancing another candidate, EDG-7500, for hypertrophic cardiomyopathy in preclinical development.
Edgewise Therapeutics (NASDAQ: EWTX) announced plans for a virtual investor call on January 3, 2023, showcasing preclinical data for its lead candidate, EDG-7500, targeting hypertrophic cardiomyopathy (HCM). Commentary will be provided by a leading cardiologist. CEO Kevin Koch stated that the preclinical data could address unmet needs in HCM treatment, with an IND application expected in the second half of 2023. Additionally, the company will present its 2023 outlook at the J.P. Morgan Healthcare Conference on January 10, 2023.
Edgewise Therapeutics (NASDAQ: EWTX) announces the appointment of Marc Semigran, M.D., as Chief Development Officer. Dr. Semigran, with extensive experience in clinical development, previously served as CMO at Renovacor and MyoKardia, leading to their acquisitions. He will guide Edgewise's cardiovascular program, aiming for an IND filing in the latter half of 2023. Dr. Semigran's expertise includes overseeing successful drug development projects, notably mavacamten for hypertrophic cardiomyopathy.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company, announced participation in two upcoming investor conferences. The Stifel 2022 Healthcare Conference will take place on November 16, 2022, at 3:00 pm ET, while the Piper Sandler 34th Annual Healthcare Conference is scheduled for November 29, 2022, at 8:30 am ET. Both presentations will be webcast live, with replay availability. Edgewise focuses on developing therapies for rare muscle disorders, notably pursuing its lead candidate, EDG-5506, in clinical trials.
Edgewise Therapeutics reported promising 6-month interim results for EDG-5506 in Becker muscular dystrophy (BMD), showing significant decreases in biomarkers of muscle damage (39% for creatine kinase, 75% for fast skeletal muscle troponin I). With a robust cash position of $365 million as of September 30, 2022, the company is advancing its clinical trials, including the CANYON Phase 2 trial for BMD and the newly initiated LYNX Phase 2 trial for Duchenne muscular dystrophy (DMD). However, net losses increased to $17.5 million for Q3 2022, compared to $16.1 million in the prior quarter.